Zobrazeno 1 - 10
of 1 932
pro vyhledávání: '"Dabigatran etexilate"'
Autor:
V. B. Vasilyuk, M. V. Faraponova, A. B. Verveda, G. I. Syraeva, Yu. B. Vikharev, A. V. Popov, A. L. Kovalenko
Publikováno v:
Российский кардиологический журнал, Vol 29, Iss 8 (2024)
Aim. To study the comparative pharmacokinetics and confirmation of bioequivalence of the generic (T) and original (R) dabigatran etexilate in healthy volunteers after a single oral dose under fasted conditions.Material and methods. To confirm bioequi
Externí odkaz:
https://doaj.org/article/f0d4f2861df44468accf235d3577a562
Autor:
G. R. Ramazanov, E. A. Kovaleva, E. V. Klychnikova, S. S. Petrikov, N. A. Shamalov, I. S. Aliev, E. V. Shevchenko
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 22, Iss 10 (2023)
The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy. In this case, DOAC use is a limitation for sys
Externí odkaz:
https://doaj.org/article/32bb45e4dec44c9c82eb0fb1f1feea28
Publikováno v:
Фармакоэкономика, Vol 15, Iss 4, Pp 407-417 (2023)
Objective: to assess the clinical and economic feasibility of ticagrelor in combination with acetylsalicylic acid (ASA) in comparison with clopidogrel in combination with ASA in patients with acute coronary syndrome (ACS), including both those who un
Externí odkaz:
https://doaj.org/article/1ac085485b204879945307dc4b3fa747
Autor:
Nikolaos PE Kadoglou, Marianna Stasinopoulou, Evangelia Gkougkoudi, Eirini Christodoulou, Nikolaos Kostomitsopoulos, Georgia Valsami
Publikováno v:
Pharmaceuticals, Vol 16, Iss 10, p 1396 (2023)
Aim: To determine the complementary effects of dabigatran etexilate (DE), exercise training (ET), and combination (DE + ET) on the development and stability of the atherosclerotic lesions in diabetic apoE knockout (apoE−/−) mice. Methods: In 48 m
Externí odkaz:
https://doaj.org/article/c76e7d93e68543e3b415b3359b7036e7
Publikováno v:
Northwestern Medical Journal, Vol 3, Iss 1 (2023)
Aim: The last standard treatment for venous thromboembolism (VTE) is oral anticoagulation with a vitamin K antagonist. Treatment with a vitamin K antagonist requires frequent monitoring of the international normalized ratio (INR), and these drugs hav
Externí odkaz:
https://doaj.org/article/36ef22a35d1c40fd8b3aec75c4118a25
Autor:
L. Kh.-B. Akhmatkhanova, G. R. Ramazanov, E. V. Klychnikova, R. Sh. Muslimov, M. V. Parkhomenko
Publikováno v:
Неотложная медицинская помощь, Vol 10, Iss 3, Pp 598-603 (2021)
This article reports the first experience of the N.V. Sklifosovsky Research Institute for Emergency Medicine in reperfusion therapy for ischemic stroke in a patient taking oral anticoagulant.
Externí odkaz:
https://doaj.org/article/c2fa7b2adc244968831cde5756f042e6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
I. S. Yavelov
Publikováno v:
Атеротромбоз, Vol 0, Iss 1, Pp 51-57 (2021)
The incidence of atrial fibrillation (AF) and coronary heart disease (CHD) increases with age. Obviously, this is largely due to the coincidence of risk factors for the occurrence and progression of AF and risk factors for the occurrence and progress
Externí odkaz:
https://doaj.org/article/0e2009eb8fa64074b27f05be34255341
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 1, Pp 146-152 (2021)
Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists. However, pharmacokinetics and pharmacogenetics of dabigatran are
Externí odkaz:
https://doaj.org/article/d192563c48064c098f3c92f3b4740431